Concisely, current evidence demonstrates the benefits of using combinations of high-dose ACE inhibitors, β-blockers, and diuretics in significantly reducing death and disability when compared to conventional therapy for patients with congestive heart failure [14]. This evidence concerns the gene ACE and congestive heart failure.